Treatment Paradigm for AD With PDE4 and Mechanism of Action Crisaborole.

Speciality: Dermatlogy

Description:

A warm welcome to all the medical professionals in this interesting session on the current treatment paradigm for Atopic Dermatitis, the role of PDE4 in AD, and the mechanism of action Crisaborole.

The current treatment paradigm for Atopic Dermatitis (AD) emphasizes a multifaceted approach targeting inflammation and itch relief. Topical corticosteroids and calcineurin inhibitors are frontline treatments, while systemic therapies may be considered for severe cases. Additionally, emerging biologic agents targeting specific immune pathways offer promising options for refractory AD.

Phosphodiesterase-4 (PDE4) inhibitors, like Crisaborole, have gained attention for their role in AD management. PDE4 regulates inflammatory responses by degrading cyclic adenosine monophosphate (cAMP), thereby modulating cytokine production. In AD, elevated levels of pro-inflammatory cytokines contribute to skin inflammation and barrier dysfunction. By inhibiting PDE4, Crisaborole reduces inflammation and restores skin barrier function, offering a targeted approach to AD treatment with favorable safety and efficacy profiles.

Therefore, get an overall knowledge of the current treatment paradigm for Atopic Dermatitis, the role of PDE4 in AD, and the mechanism of action Crisaborole. Listen to the webinar, grab the shared knowledge, and follow Hidoc for more such interesting webinar sessions.
 

See More Webinars @ Hidoc Webinars